Is adalimumab effective for ankylosing spondylitis?

Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the spine and pelvic joints. It usually presents with chronic pain, stiffness and limited mobility in the lower back. Ankylosing spondylitis is an autoimmune disease in which the immune system mistakenly attacks healthy tissue, causing chronic inflammation and bone damage. Adalimumab(Adalimumab), as an anti-TNF-α monoclonal antibody, has demonstrated significant efficacy in the treatment of ankylosing spondylitis.

Adalimumab can effectively alleviate the clinical symptoms of ankylosing spondylitis by inhibiting tumor necrosis factorα (TNF-α) and reducing the inflammatory response. TNF-α is one of the main causative factors in inflammatory diseases such as ankylosing spondylitis. Adalimumab helps reduce joint inflammation, relieve pain, and improve patients' mobility by targeting and blocking the effects of TNF-α. Studies have shown that adalimumab can effectively reduce inflammation, reduce early joint damage, and improve patients' functional status in patients with ankylosing spondylitis.

Clinical studies have shown that patients with ankylosing spondylitis who receive adalimumab often experience significant reductions in pain, stiffness, and improved ability to perform daily activities. In addition, adalimumab has been found to be effective in improving spinal mobility and flexibility and reducing dysfunction caused by inflammation. These therapeutic effects have made adalimumab one of the standard drugs for the treatment of ankylosing spondylitis, especially in patients who do not respond well to traditional drugs such as nonsteroidal anti-inflammatory drugs and other anti-rheumatic drugs.

However, although adalimumab is effective in many patients, it still may not have the desired effect in every patient. Some patients may develop drug resistance or side effects during treatment. Therefore, doctors usually adjust the medication regimen based on the patient's condition development and treatment response.

Reference materials:https://www.drugs.com/adalimumab.html